2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited States
2015
Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?
Pitzer VE, Bilcke J, Heylen E, Crawford FW, Callens M, De Smet F, Van Ranst M, Zeller M, Matthijnssens J. Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium? Scientific Reports 2015, 5: 18585. PMID: 26687288, PMCID: PMC4685644, DOI: 10.1038/srep18585.Peer-Reviewed Original ResearchConceptsVaccine introductionStrain-specific vaccine effectivenessVaccine-derived immunityRotavirus vaccine introductionVaccine-induced immunityAbsence of vaccinationRotavirus populationLarge-scale vaccinationDistribution of genotypesRotavirus gastroenteritisVaccine effectivenessHomotypic strainHospitalization dataPredominant rotavirusStrain replacementVaccinationVaccineImmunityInfectionViral populationsPopulationGastroenteritisYearsIncidenceRotavirus
2012
Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings
Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, Gambhir M, Atchison C, Grenfell BT, Edmunds WJ, Kang G, Parashar UD. Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings. PLOS ONE 2012, 7: e41720. PMID: 22879893, PMCID: PMC3412858, DOI: 10.1371/journal.pone.0041720.Peer-Reviewed Original ResearchConceptsLow socio-economic settingRotavirus vaccine efficacyVaccine efficacyRotavirus vaccineSevere diseaseNatural infectionImmunogenicity of vaccinationReduced vaccine efficacySevere rotavirus gastroenteritisReduced efficacyClinical trial resultsLow SES populationsRotavirus gastroenteritisVaccine performanceVaccination programImmune responseEpidemiological factorsVaccineVaccinationTrial resultsInfectionSES populationsEfficacyReduced protectionEfficacy declines
2005
Anaplasma phagocytophilum in White-tailed Deer - Volume 11, Number 10—October 2005 - Emerging Infectious Diseases journal - CDC
Massung R, Courtney J, Hiratzka S, Pitzer V, Smith G, Dryden R. Anaplasma phagocytophilum in White-tailed Deer - Volume 11, Number 10—October 2005 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2005, 11: 1604-1606. PMID: 16318705, PMCID: PMC3366735, DOI: 10.3201/eid1110.041329.Peer-Reviewed Original Research